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Purpose: To provide a comprehensive overview of the basic science and clinical evidence behind carti-
lage regeneration techniques as they relate to surgical management of chondral lesions in humans.
Methods: A descriptive review of current literature.
Results: Articular cartilage defects are common in orthopedic practice, with current treatments yielding
acceptable short-term but inconsistent long-term results. Tissue engineering techniques are being
employed with aims of repopulating a cartilage defect with hyaline cartilage containing living chon-
drocytes with hopes of improving clinical outcomes. Cartilage tissue engineering broadly involves the
use of three components: cell source, biomaterial/membranes, and/or growth stimulators, either alone or
in any combination. Tissue engineering principles are currently being applied to clinical medicine in the
form of autologous chondrocyte implantation (ACI) or similar techniques. Despite reﬁnements in tech-
nique, current literature fails to support a clinical beneﬁt of ACI over older techniques such as micro-
fracture except perhaps for larger (>4 cm) lesions. Modern ACI techniques may be associated with lower
operative revision rates. The notion that ACI-like procedures produce hyaline-like cartilage in humans
remains unsupported by high-quality clinical research.
Conclusions: Many of the advancements in tissue engineering have yet to be applied in a clinical setting.
While basic science has reﬁned orthopedic management of chondral lesions, available evidence does not
conclude the superiority of modern tissue engineering methods over other techniques in improving
clinical symptoms or restoring native joint mechanics. It is hoped further research will optimize ease of
cell harvest and growth, enhanced cartilage production, and improve cost-effectiveness of medical
intervention.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Articular cartilage defects are commonly encountered in or-
thopedic practice but still represent a treatment challenge with
inconsistent long-term results1. Articular cartilage is an avascular
tissue composed of chondrocytes dispersed within an extracellular
matrix (ECM) comprised of collagen and proteoglycans2. Found at
the articulating end of bones, hyaline cartilage provides a low
friction interface that also bears load3. Formed initially fromJ. Theodoropoulos, University
sity Ave, Suite 476C, Toronto,
; Fax: 1-416-586-8501.
ca (B. Mollon), rkandel@
Chahal), jtheodoropoulos@
s Research Society International. Pundifferentiated mesenchymal cells, chondrocytes synthesize
cartilage matrix composed of 60% collagen (type II predominant),
25% proteoglycans, and 15% glycoproteins4. The composition of
cartilage matures during progression to adulthood, resulting in a
zonal organization of superﬁcial, middle and deep calciﬁed layers
that are anchored into subchondral bone5. Overall, maturation re-
sults in a seven-fold increase in collagen cross-linking, and a 450%
increase in the tensile and 180% increase in the compressive
modulus of cartilage6,7. While chondrocytes are primarily involved
in articular cartilage maintenance through the synthesis of ECM,
overall cartilage homeostasis is thought to be the product of a
complex interplay between joint mechanics, growth factors, hor-
mones and aging4.
Although our understanding of these processes is evolving, a
chondral lesion can simply be thought of as the inability of matrix
synthesis to counter-act destructive forces placed on a joint. Onceublished by Elsevier Ltd. All rights reserved.
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human adult articular cartilage has a limited ability to spontane-
ously heal, especially for larger defects (>3mm), defects that do not
breach the subchondral plate, or in older patients4. Reasons for the
ineffective reparative response after damage are thought to include
the inability of chondrocytes to migrate to the site of injury, the
avascular nature of cartilage, and the absence of a ﬁbrin clot
scaffold1,8.
While a range of clinical options exist for the treatment of
cartilage defects, the majority of current treatment options are
aimed at symptom relief and fall short of the goal of recreating pre-
injury joint mechanics with the biologic capacity of long-term
healing (see Table I for a summary of current management op-
tions). At one end of the spectrum, symptomatic relief may be
obtained with oral analgesia, weight loss, physiotherapy to
strengthen deconditioned muscles or arthroscopic chondroplasty,
which aims to shave off the loose cartilage margins thought to be
involved in mechanical joint irritation. These processes address
pain, but fail to address the chondral lesion and thus are thought to
not adequately address the longer-term sequela of cartilage injury:
the development of osteoarthritis9. At the other end, joint arthro-
plasty can be performed in most major synovial joints to replace a
severe osteoarthritic process with a metallic prosthesis. While this
procedure affords good quality of life (QOL), it is not appropriate for
young individuals as the risk of failure increases over time and the
functional limitations of a prosthesis are likely not adequate for an
otherwise active or working individual. In between these two types
of treatment modalities ‘biological’ cartilage treatments broadly
attempt to ﬁll the cartilage defect with stimulated ﬁbrocartilage
growth (i.e., microfracture) or a chondrocyte-containing plug [e.g.,
osteochondral transfer, mosaicplasty or autologous chondrocyte
implantation (ACI)]10.
The ideal treatment would reestablish the low friction proper-
ties of cartilage with the ability to resist wear over time by repo-
pulating a lesion with chondrocytes able to produce a hyaline
matrix that is fully integrated with surrounding host cartilage. The
goal of creating integrative hyaline cartilage within a joint will
theoretically improve joint mechanics and delay or even stopTable I
Current clinical options for the treatment of cartilage defects1,10
Treatment Description Be
Non-surgical Oral analgesia, weight loss, physiotherapy Ma
Arthroscopic
chondroplasty
Minimally invasive resection of loose cartilage
to decrease mechanical joint irritation
Sim
we
Microfracture Minimally invasive arthroscopic surgical
procedure that breaches the subchondral bone
with a pick to release osteoprogenitor cells
into a defect to encourage ﬁbrocartilage growth
Mi
gra
su
us
Mosiacplasty/
osteochondral
autograft transfer
Uses multiple osteochondral autografts harvested
from the patients femur to ﬁll an osteochondral
defect
No
in
Us
1e
ACI Harvested chondrocytes are cultured prior to
being re-implanted into the defect. An evolving
procedure due to advances in tissue engineering
Ma
ca
Osteochondral
allograft transfer
Uses allogenic (cadaveric) osteochondral tissue
to ﬁll defect
Ca
sit
Joint arthroplasty Resects and replaces arthritic bone with an
artiﬁcial joint, most commonly metal implants
(i.e., cobalt chrome) separated by a polyethylene
liner
Pa
to
A list of currently available treatment options for cartilage defects, most commonly used t
treatment of smallest to largest defects. The bulk of this article will focus on ACI and its
* Note: no therapy has been shown to alter the natural history of a chondral lesion (i.osteoarthritic progression within a joint. Hope lies in the area of
tissue engineering to achieve this goal.
The purpose of this article is to describe the principles of tissue
engineering in the context of cartilage regeneration in humans.
Both the current status and future directions of tissue-engineered
cartilage will be explored.
Principles of cartilage tissue engineering
Tissue engineering principles emerged in the late 1980s with
the goal of reconstituting the structure and function of human
tissues8. This approach has since been investigated intensively and
there is proof-of concept evidence to support cell-based regener-
ation of cartilage tissue11. With tissue engineering, researchers have
been able to create biologically active, two or three-dimensional
cartilage-like tissue complete with chondrocytes and supporting
matrix that can ﬁll a chondral lesion. Although complex, the overall
process can be distilled down to three basic components: cells,
scaffolds/matrix, and/or growth stimulators8. Cells must be capable
of maintaining the articular chondrocyte phenotype or stimulate
the differentiation of other cell types into chondrocytes and accu-
mulate hyaline cartilage matrix. A structural matrix or scaffold will
facilitate the formation of a cartilage matrix. Finally, growth or
matrix stimulators in the form of biological, chemical or mechan-
ical stimulation will encourage appropriate cellular growth and
matrix synthesis on the scaffold in vivo or vitro8,11.
Cell sources for chondral repair
First and foremost, cartilage tissue engineering necessitates a
large number of chondrocytes capable of creating hyaline carti-
lage11. Unfortunately, the cell source also serves as the main
limiting factor to clinical translation as, due to low cellularity, only a
small number of primarily obtained autologous chondrocytes can
be directly harvested from an individual. As a result, several other
sources of chondrocytes have been identiﬁed including passaged
chondrocytes, induced pluripotent cells (IPCs), mesenchymal stro-
mal cells (MSCs), and human embryonic stem cells (hESCs)11.neﬁts Limitations*
y avoid surgery Only masks symptoms, chronic use of pain
medications
ple procedure, immediate
ight bearing
Only masks symptoms
nimally invasive, no tissue
fts required, only routine
rgical instruments needed,
ed for lesions <2.5 cm2
Fibrocartilage biomechanically inferior to
hyaline cartilage, brief period of non-weight
bearing, unclear impact on development of
arthritis
allograft, theoretically ﬁlls
with hyaline cartilage.
ed to treat lesions from
4 cm2
Graft-site mismatch may not recreate native
joint mechanics, graft-site morbidity, cannot
treat large lesions, lack of integration with
surrounding tissues
y produce hyaline cartilage,
n treat lesions 2e10 cm2
Graft delamination, periosteal hypertrophy,
questionable ability to produce hyaline
cartilage
n treat large lesions, no graft-
e morbidity
Allogenic tissue (potential for disease
transmission), size/depth mismatch,
questionable chondrocyte viability, lack of
integration with surrounding tissues
in relief, variable return
function
Variable return to function/activity
limitations, infection, Implants wear out
over time (need for re-operation), cannot
completely recreate native anatomy or
mechanics
o treat lesions in the knee. The list is ordered from least to most invasive, and for the
evolution due to research into cartilage tissue engineering.
e., progression to osteoarthritis), thus serving as a limitation for all therapies.
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Marrow stimulation techniques, which can be considered a
precursor to tissue engineering, include osteochondral drilling,
abrasion chondroplasty and microfracture1. These techniques all
seek to stimulate the release of chondroprogenitor cells into the
defect to encourage the formation of ﬁbrocartilage (composed of
type I and type II collagen).While often the simplest option for small
isolated defects, ﬁbrocartilage is mechanically inferior to hyaline
cartilage (composed of type II collagen)12. For that reason, marrow
stimulation techniques can be considered a pain-relieving proce-
dure that at most slows the progression towards osteoarthritis9,13.
Osteoarticular transplant procedures use native chondrocyte-
containing cartilage with underlying bone. Given the described
complexity of the structure of cartilage, the allure of repairing a
chondral lesion with structurally mature tissue obtained from
either a cadaver (allogeneic transplant) or non-weight bearing zone
of the articular surface from the patient’s own body (autologous
transplant) is understandable. Although very useful, concerns over
donor site morbidity, chondrocyte viability, disease transmission
from allogeneic tissue, and lack of integrationwith the margins of a
chondral defect are challenges that remain to be overcome by such
procedures14e16.
The procedure most related to human tissue engineering is ACI.
First described in rabbits by Grande et al.17 and later in humans by
Brittberg et al.18 to treat knee chondral lesions, ACI uses arthro-
scopically harvested chondrocytes that are subsequently cultured
in monolayer (so-called ‘passaged chondrocytes’). The chondrocyte
suspension is then implanted into the defect and sutured under a
watertight periosteal patch. This treatment, which requires two
operations spaced six to 8 weeks apart, was originally indicated in
patients with focal lesions 2e10 cm2 in size18. Randomized clinical
trials have yielded mixed results on the ability of ACI-like pro-
cedures to produce enhanced structural repair over microfracture,
with minimal clinical differences at 5 years19,20. While clinical re-
sults are generally favorable, risks include periosteal hypertrophy,
delamination of the graft and arthroﬁbrosis21,22. In addition, the
ability of ACI to reliably produce hyaline-like cartilage has been
challenged, with some animal models suggesting that some healing
is stimulated by the ingrowth of progenitor cells from breached
subchondral bone or from the periosteal patch23,24. Furthermore,
culturing chondrocytes in monolayer culture to increase cell
numbers, known as passaged chondrocytes, results in a decreased
capacity to produce hyaline-like matrix due to chondrocyte de-
differentiation25,26.
A variant of ACI is found in procedures utilizing particulated
articular cartilage. Animal and subsequent clinical studies have
demonstrated minced cartilage without bone or cell culture canTable II
Generational development of autologous chondrocyte-like implantation techniques
Generation Description
First Autograft chondrocytes are obtained via arthroscopy, expanded in cult
under a periosteal or collagen patch during a second operation.
Second Autograft chondrocytes are obtained via arthroscopy, chondrocytes are
and the chondrocyte/scaffold complex is inserted into the knee at a lat
a periosteal/collagen patch.
Third Introduces either chondro-conductive or -inductive scaffolds, xeno/allo
graft constructs, or mechanically conditioned chondrocytes during the
Fourth Utilizes stromal cells, stem cells, or gene therapy to produce chondrocy
The application of tissue engineering research has lead to a gradual reﬁnement in ACI-Lik
decreasing patient morbidity), increase the reliability of hyaline cartilage formation, imp
Note: Matrix-Induced Autologous Chondrocyte Implantation (MACI) procedures refer to sprovide a cell source for cartilage repair27,28. Chondrocytes from
minced cartilage display a standard chondrocyte phenotype and are
through to migrate from the graft ECM, multiply and form hyaline-
like cartilage integrated with native tissue28. Available commercial
products include deNovo NT (Zimmer, Inc., Warsaw, IN) and Carti-
lage Autograft Implantation System (CAIS; DePuy Mitek Inc., Rayn-
ham, MA)29. CAIS utilizes autogenous cartilage tissue harvested
intra-operatively and distributed on a polycaprolactone/poly-
glycolic acid scaffold secured under a polydiaxone mesh, while
deNovo NT utilizes particulated viable juvenile allograft hyaline
cartilage pieces that are secured into a defect with ﬁbrin glue. Both
products and have found promising short-term results29.
The application of tissue engineering principles has resulted in
the progressive reﬁnement of the ACI-like procedures to address
some of the above shortcomings. For example, we have shown that
passaged chondrocytes that have adapted a ﬁbroblast-like
morphology can undergo redifferentiation when co-cultured with
non-passaged (or primary) chondrocytes and reacquire the ability
to form hyaline cartilage25,26. The mechanism underlying this
redifferentiation is unclear, but may be related to direct cellecell
communication, ECM microenvironment produced by chon-
drocytes, or paracrine signaling30,31. Regardless, these cells could
then be used to redifferentiate other passaged chondrocytes, thus
forming a stable phenotype that could be utilized in ACI pro-
cedures26. Additional studies are required to evaluate the efﬁcacy of
our co-culture method in vivo.
The evolution of ACI has resulted in four described ‘generations’
that have been expanded upon in other reviews32,33. We propose
the following divisions between ACI generations in Table II, with
each generation using more advanced tissue engineering technol-
ogies. Clinically, each generation is thought to represent a move
towards less patient morbidity (i.e., arthroscopic instead of open
procedures; or one-stage operations) or the enhanced production
of hyaline cartilage.
MSCs
MSCs are multipotent cells capable of differentiation into oste-
ocyte, adipocyte and chondrocyte lineages under the appropriate
conditions34. Deﬁned by their expression of certain cell surface
molecules (i.e., CD73, CD105, CD90) and their ability to grow as
adherentﬁbroblast-like cells in vitro, MSCs are referred to as stromal
cells instead of previously named stem cells as they are ultimately
restricted in the type of cells into which they can differentiate35.
The process of collecting, isolating and growing MSCs from
various sources is beyond the scope of this article (see review by
Archer et al.36). In brief, cells are obtained via bone marrow aspi-
ration or tissue enzymatic degradation and expanded in culture.Deﬁning features
ure, and re-implanted Periosteal/collagen patch used AND no scaffolds
expanded on a scaffold,
er operation without
Basic scaffolds AND no periosteal patch
geneic cells, biphasic
culturing process.
Utilizes all three components of tissue engineering
(introduces growth factors/mechanical conditioning)
OR introduces non-self cell types OR attempts to
reproduce zonal architecture of mature cartilage
tes. Stem cells/gene therapy for chondrogenesis
e techniques. Each generation is thought to allow for a less invasive procedure (thus
rove graft uptake or decrease the number of surgical procedures required.
econd-generation or older ACI procedures depending on the type of matrix utilized.
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surface markers. Culture conditions are then optimized to induce
differentiation into the desired cell line,36 in this case chondrocytes.
Bone marrow represents the main source of MSCs (so-called
bmMSCs), although umbilical cord, adipose tissue, synovial mem-
brane and articular cartilage represent alternate sources. It should
be noted that MSCs obtained from varying cellular sources express
differing densities and types of cell surface proteins/markers36. For
example, CD34þ is identiﬁed only on adipose derived MSCs, Tissue
Non-Speciﬁc Alkaline Phosphatase (TNAP) is exclusively found on
bmMSCs, and Stage Speciﬁc Embryonic Antigen 4 (SSEA-4) is
expressed by placenta derived MSCs36,37. These differences may
reﬂect differences in chondrogenesis noted amongst MSC cell lines
in some studies. For example, a comparison of bone marrow, adi-
pose derived, muscle derived or synovial derived stromal cells
obtained from the same individual revealed synovial derived cells
had a superior potential for chondrogenesis38 and produced larger
cartilage aggregates over time39 when compared with bmMSCs.
The clinical utility of this ﬁnding is unclear, as synovium-derived
MSCs have yet to be used in humans40, and as previously
mentioned the cellular composition and presence of environmental
stimuli may be as important as the origin of the stromal cell.
Cellular responses to growth factors or scaffolds may differ not only
between different sources of MSCs but also within them. For
example, Battula et al. utilized monoclonal antibodies to identify
antigens associated with rapidly growing bmMSCs: CD271 and
CD5641. Cells expressing both antigens proliferated more than 30
times faster than an unsorted pool of bmMSCs. The results of this
study also suggest that cells expressing CD271, CD56 and TNAP
preferably generated chondrocytes and displaying decreased adi-
pogenic potential41.
MSCs are commonly utilized in tissue engineering, with
bmMSCs being the most common cell source utilized clinically in
humans36. For example, in an observational cohort study by
Nejadnik et al.42 ACI was compared with a group that received a
similar treatment using autologous bmMSCs instead of chon-
drocytes. The authors concluded there was no difference in clinical
outcome between groups at 24 months after surgery42. Addition-
ally, Wakitani et al.43 utilized culture expanded autologous
bmMSCs embedded on a collagen sheet for the treatment of
patellofemoral joint chondral defects in a small case series. The
bmMSCs were transplanted into the defect and secured with a
periosteal graft or synovium (similar to ﬁrst generation ACI tech-
niques), with symptomatic improvement noted for as long as 27
months43. Longer-term follow-up studies have conﬁrmed this to be
a safe procedure without development of tumor or infections in a
group of 40 patients over 11 years40. These results suggest at the
very least equivalence in clinical outcome between implantation of
chondrocytes or bmMSCs in ACI-type procedures in terms of short-
term symptomatic relief. While biopsies obtained during second
look arthroscopies suggest the presence of hyaline-like cartilage in
both the bmMSCs and ACI group in one trial42, this is based on a
small subset of the original study population requiring arthroscopy
for symptomatic knees. Thus, true superiority of bmMSCs over
earlier generation ACI techniques remains unproven.
ESCs
ESCs are deﬁned by their ability to proliferate in an undiffer-
entiated state for a prolonged period while maintaining the capa-
bility to differentiate into any mature cell in the body, including
chondrocytes. First described by Thomson et al.44, ESCs are ﬁrst
obtained from the inner cell mass of blastocyst-stage embryos.
After this, progression towards viable chondrocytes can occur
either through the formation of an embryoid body (EB) andsubsequent selection of mesodermal cells, or by ﬁrst transforming
ESCs into MSCs before pursuing a chondrogenic phenotype via
growth factors or sorting by surface antigens (see previous sec-
tion)45,46. Challenges with both these techniques include difﬁcultly
in guaranteeing a pure population of chondrocytes when manip-
ulating pluripotent cells, the potential for ESCs that have differen-
tiated to chondrocytes to undergo de-differentiation into other
lineages (i.e., skeletal muscle), and to date no one has produced
sufﬁcient hyaline cartilage tissue from ESCs suitable for joint
resurfacing47e49. Safety concerns are paramount, as undifferenti-
ated residual ESCs are known to be tumorogenic45. Recent animal
studies have suggested that injection of ESCs into a joint cavity
results in teratoma formation, while localized injection into
osteochondral defects does not50,51. Additionally, joint immobili-
zation may encourage tumor formation while joint mobility en-
courages chondrogenesis52. While showing promise, additional
work is required to better understand the factors involved in pro-
ducing a clinically suitable, homogenous chondrocyte population
from hESCs. Indeed, no trial in humans has as yet been published,
although animal studies have been reported53,54.
Induced Pluripotent Stem Cells (iPSCs) are an alternate method
of creating cells with ESC-like properties. As originally described by
Takahashi and Yamanaka55, mouse ﬁbroblasts can be transduced
with the transcription factors Oct3/4, Sox2, Klf4 and c-Myc, trans-
forming them into cells with ESC-like pluripotency. IPSC express
ESC cell marker genes and demonstrate ESC-like growth capabil-
ities, including potential for teratoma formation. Since this dis-
covery, many other cell types have been induced to acquire ESC-like
phenotype56. Recently Wei et al.57 described the trans-
differentiation of human chondrocytes into iPSCs. The develop-
ment of DNA alterations and genomic instability in iPSCs are issues
that need to be addressed as well before these technological ad-
vances can be applied clinically56.Scaffolds
Scaffolds are three-dimensional chondro-condusive biomaterials
which facilitate chondrocyte number expansion and/or organiza-
tion while also providing a mechanically stable support for human
chondrocyte implantation58. Of note, ‘chondro-conductive’ sub-
stances support chondrocyte growth whereas ‘chondro-inductive’
substances induce the differentiation to, and maintenance of, the
chondrogenic cellular phenotype. Safran et al.58 listed the re-
quirements for the ideal scaffold including: biocompatible, biode-
gradable, permeable, noncytotoxic, mechanically stable, able to
support chondrocyte growth, versatile, readily available and easy to
manufacture. Additionally, appropriate porosity is considered
another characteristic, with pore sizes between 100 mm and 300 mm
thought to best optimize cellular seeding and differentiation while
facilitating waste/nutrient dispersion59. Scaffolds currently repre-
sent a key component in chondrogenic differentiation of the
aforementioned cell lineages as the three-dimensional environment
is believed to facilitate the cellular and cellematrix interactions
encouraging chondrogenesis60. For that reason, the scaffolds have
been used to augment microfracture or ACI-type procedures by
facilitating chondrocyte transfer and speeding graft incorporation
with the ultimate hope of increasing the proportion of ‘hyaline’ or
‘hyaline-like’ cartilage10,61,62.
Available scaffolds fall into one of four broad categories: protein,
carbohydrate, synthetic and composite. Protein-based scaffolds
include collagen, gelatin and ﬁbrin; carbohydrate polymers include
hyaluronan, alginate, alginate, and polylactic/polyglycolic acids;
and synthetic scaffolds include Teﬂon, carbon ﬁber, Dacron, and
hydroxyapatite58.
Table III
Known actions of growth factors in chondrogenesis
Transforming Growth Factor B (TGF-b) Superfamily71
Anabolic effect on chondrocytes
Maintains chondrocyte phenotype
Redifferentiates passaged chondrocytes
TGF-b1 promotes cell proliferation and inhibits matrix metalloproteinases84
GDF-5 upregulates GAG and type II collagen production by hMSC derived
chondrocytes85.
Bone Morphogenic Proteins (BMPs; Member of TGF-b Superfamily)
Encourage undifferentiated mesenchymal cells towards chondrocyte
phenotype86
BMP-2 enhances redifferentiation of passaged chondrocytes87
BMP-4 and BMP-6 increase type II collagen and the accumulation of
proteoglycans while decreasing type I collagen synthesis88,89
BMPs-2, -12 (GDF-7) and -13 enhanced collagen, GAG and cellular growth of
cultured chondrocytes90.
IGFs
IGF-1 encourages chondrocyte proliferation91
IGF-1 (with TGF-b1) promotes proteoglycan accumulation, type II collagen
synthesis and maintenance of chondrocyte phenotype92
IGF-1 binds to proteoglycans via IGF-binding protein, thus being release to
counter-act cartilage breakdown during periods of catabolism93
Insulin promotes chondrogenesis94
FGF
(þ/) Mixed results on promotion of cartilage repair95,96
Encourages articular cartilage cell number expansion (in monolayer)97
(ve) Suppresses proteoglycan synthesis98
(ve) Flattens chondrocytes, encourages ﬁbroblast morphology99
(ve) Inhibits terminal differentiation of articular chondrocytes100
This table explores our evolving knowledge of major growth factors in chondrocyte
regeneration.
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One of the most commonly used scaffolds is collagen, a natural
scaffold which also contains sites for cellular adhesion and has been
shown to inﬂuence chondrocyte differentiation63,64. Collagen
scaffolds have also been utilized to enhance marrow stimulation
techniques, with scaffolds being inserted post-microfracture as a
one-step procedure. One commercial example is Chondro-Gide
(Geistlich Pharma AG, Wolhusen, Switzerland), a I/III collagen
scaffold used in a technique termed Autologous Matrix-Induced
Chondrogenesis (AMIC) with promising non-comparative 2-year
results but a paucity of data suggesting structural superiority over
microfracture alone62. Collagen scaffolds have also been used
instead of periosteal patches to secure cultured chondrocytes to
cartilage defects in ACI procedures (see NeoCart, Histogenics,
Waltham, MA)63 and have displayed promising short-term re-
sults63,64, but longer-term outcomes are required.
Hyaluronic acid-based scaffolds such as Hyalograft C (Anika
Therapeutics, Bedford, MA) have also been utilized in cartilage
regeneration61. These carbohydrate-based polymers have the pro-
posed beneﬁt of being fully resorbed in 3 months after being
degraded to hyaluronan and are thought to encourage chondro-
genic differentiation as evident by an increased presence of type II
collagen and aggrecan with a decrease in type I collagen65. While
published clinical trials suggest good outcomes with hyaluronic
acid-based grafts at 3 years after implantation, with a high per-
centage displaying hyaline or “hyaline-like” cartilage 18 months
post implantation61, this product is not available in North America
and was recently withdrawn from the European market by the
manufacturer.
Exciting potential exists for hydrogel scaffolds. Hydrogels are a
liquid polymer that can be stimulated to undergo cross-linking to
form a water-insoluble gel66. Materials investigated for this prop-
erty include: alginate, ﬁbrin, and synthetic polymers of poly-
ethylene oxide and poly propylene oxide. There are many
theoretical beneﬁts to this technology: the ability of growth factors
to diffuse through the gel, water content that mimics native carti-
lage, and the injectable nature that facilitates arthroscopic inser-
tion. One hydrogel in clinical use is Gelrin C (Regentis, Haifa,
Isreal). Gelrin C is a bioabsorbable photopolymerized hydrogel of
polyethylene glycol diacrylate bound to ﬁbrinogen and degrades
within 6e12 months67. It is injected into a previously micro-
fractured defect as a gel that polymerizes in situ. In vitro, Gelrin C
exhibits innate chondrogenic and osteoconductive potential, is
nonimmunogenic, and in an ovine model demonstrated type II
collagen and proteoglycan synthesis in treated vs untreated de-
fects68. This product is being investigated in an ongoing multi-
center clinical trial.
While chitosan/glycerol copolymer marketed as BST-Cargel
(Piramal Healthcare Ltd, Vikhroli West, Mumbai), has shown
promise in previous studies69 and is being investigated in phase III
clinical trials, few other types of scaffolds have been clinically
investigated in humans.Growth factors
As chondrocyte or stromal cell growth is regulated by an
interplay between mechanical and chemical stimuli70, guided uti-
lization of growth factors is advantageous when engineering
cartilage. Growth factors are considered to be chondro-inductive
substances and the factors commonly associated with cartilage
growth and maturation fall into one of three broad categories: the
Transforming Growth Factor-b (TGF-b) family, Insulin-like Growth
Factors (IGFs) and Fibroblast Growth Factor (FGF)70,71.The known actions of major chondrogenic growth factors are
summarized in Table III. Broadly, these factors are thought to be
involved in maintaining chondrocyte phenotype during monolayer
passaging, encouraging chondrogenic differentiation of stem cells
or stromal cells, maintaining chondrocyte phenotype, and
encouraging collagen type II synthesis70e72. For example, human
ESCs and mesodermal cells undergo chondrogenic differentiation
in the presence of growth factors such as TGF-b and BMP-248,49,73.
Additionally, cell lines can be genetically engineered to express
proteins whose goal is to enhance chondrogenicmatrix production,
such as type II collagen. For example, Kuroda et al.74 genetically
engineeredMDSCs to express BMP-4 and found type II collagenwas
expressed as early as 4 weeks in rats. Cell lineage also impacts
growth factor activity. For example, aggrecan upregulation occurs
when bmMSCs are exposed to TGF-b3, while BMP-6 is needed to
upregulate aggrecan on adipose derived MSCs75. Our clinical un-
derstanding of the roles of growth factors in the production of an
articular chondrocyte phenotype in humans is evolving, but addi-
tional work is required.
Another way to administer growth factors in a less directed
manner is Platelet-Rich Plasma (PRP), a growth factor-rich
concentrate that can be easily acquired through centrifugation of
patient’s own blood creating an autologous preparation of serum
with high concentrations of platelets, cytokines, and growth fac-
tors. The application of PRP acts to amplify the concentration of
chemical mediators in the microenvironment of the injured area
such as TGF-b1, IGF-1, Vascular Endothelial Growth Factor (VEGF),
and Platelet-Derived Growth Factor (PDGF), among others71. In vitro
studies maintaining chondrocytes in the presence of PRP instead of
fetal bovine serum have shown increased proliferation of human
chondrocytes76. Additionally, MSC’s cultured in the presence of PRP
can demonstrate differentiation towards chondrogenic and osteo-
genic lineages77,78. This technique may be used in the future as a
way to deliver autologous growth factors to chondrocytes
expanded in vitro prior to in vivo use.
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It is hoped that advances in the three components of tissue
engineering will lead to improved patient outcomes. Unfortunately,
most developments in cartilage tissue engineering have yet to
translate into measurable clinical gains or have yet to be applied to
human populations due to novelty and/or safety concerns. The
main orthopedic utilization of tissue engineering has focused on
enhancing either marrow stimulation (i.e., AMIC) or ACI-type
techniques.
Many recent systematic reviews on ACI have been published,
most often comparing ACI to stimulatory (i.e., microfracture)
techniques22,79e82. Vasiliadis et al.80 conducted a systematic review
of randomized trials comparing various ACI treatments to other
available treatment options (e.g., microfracture, mosaicplasty).
They identiﬁed nine trials and found no superiority of ACI over
other treatments. Nonetheless, they concluded that the evidence
was of poor quality and too heterogeneous to make any deﬁnitive
clinical recommendations80. A similar review of nine studies was
conducted by Vavken et al.81. In contrast to the previous review,
their data suggested that among high-quality trials, ACI resulted in
better clinical outcomes and tissue quality when compared to
osteochondral grafts. However, the authors noted that the differ-
ences between groups were small and may not reﬂect clinical sig-
niﬁcance, and ultimately concluded that additional research is
required81.
Harris et al.82 elaborated on differences between studies in their
review of level I and II evidence. Of seven studies comparing
microfracture to ACI, they found three trials showed better clinical
results with ACI after 1e3 years follow-up, one study reporting
better results after microfracture at 2 years, and three trials
reporting no difference after 1e5 years. They found a defect size of
>4 cm2 predicted better outcomes with ACI when compared to
other treatments. There was no apparent difference between open
or arthroscopic procedures, or ﬁrst and second-generation ACI
techniques82.
Clinicians must also consider the complications of a procedure
before making a recommendation. Harris et al.22 reviewed all fail-
ures and complications from ACI therapies published in 82 studies.
An overall failure rate of 5.8% was noted for ACI procedures, with a
mean time to failure at 22 months. Techniques utilizing periosteal
patches had the highest failure rates (7.7%), with lower failure rates
for all arthroscopic procedures (3.3%) or those using second-
generation ACI techniques (0.83%). ACI techniques using perios-
teal patches were associated with an unplanned re-operation rate
of 27%, which decreased to 5% in second-generation ACI, and 1.4% in
all arthroscopic second-generation ACI techniques22. Taken along
with the preceding reviews, the available literature has yet to
identify a functional beneﬁt to evolving ACI techniques but the
overall complication rates and need for re-operation has decreased
in all arthroscopic and second-generation techniques22,80e82.
Available data on third generation techniques are mostly limited
to prospective safety trials63,83. Crawford et al.63 evaluated the
safety of the third generation NeoCart procedure in a small pro-
spective trial. The eight enrolled patients had improved pain,
function and range of motion at 2 years. MRI-measured defect ﬁll
was found to be 67e100% in six patients; 33e66% in one patient
and less than 33% in one patient. No serious complications were
associated with the implant. A small sample and lack of a com-
parison group ultimately limited the strength of this study63. Cole
et al.83 presented a randomized controlled trial (RCT) involving 29
patients to establish the safety of using the Cartilage Autograft
Implantation System (CAIS; DePuyMitek, Inc., Raynham,MA)when
compared to microfracture. CAIS utilizes minced autologous hya-
line cartilage placed on an absorbable polyglycolic acid-polycaprolactone scaffold and afﬁxed using absorbable poly-
diaxonone staples. The authors found general improvement in
clinical outcomes in both groups, although the CAIS group signiﬁ-
cant improvements in the clinical rating scales over the micro-
fracture group at 24 months of follow-up. Radiographic evaluation
of lesion ﬁll and tissue integrationwas similar between groups. The
microfracture group had signiﬁcantly higher rates of intralesional
osteophyte formation at 6 and 12months. From this they concluded
the CAIS is safe and effective but acknowledged their study was
limited by small sample size, and may have been inﬂuenced by
differences between study populations (more patients with acute
onset of symptoms, more men and more full-time workers in the
CAIS group)83. Neither of the above trials discussed the histological
quality of the repair tissue (i.e., ﬁbrocartilage vs hyaline-like
cartilage)63,83.
Considering the high cost associated with engineering chon-
drocytes with equivocal clinical data, there has only been one study
focusing on the cost-effectiveness of these therapies. While Clar
et al.79 attempted a cost-comparison analysis in their systematic
review of four RCTs, they were unable to generate conclusions due
to limited evidence. They acknowledge that the QOL gain of ACI
would need to be 70e100% greater than microfracture over 2 years,
or alternatively 10e20% maintained over 10 years, to justify the use
of ACI79. While it is hoped that the theoretical beneﬁt of ACI in the
generation of durable hyaline cartilage may justify its use, clinical
evidence demonstrating beneﬁt of ACI over other techniques in this
area is sparse. Furthermore, long-term studies are required to
support the assertion that the hyaline cartilage (vs ﬁbrocartilage)
results in improved long-term biomechanical properties that de-
lays or prevents the development of osteoarthritis. Thus, based on
the above economic analysis and available long-term data, the cost-
effectiveness analysis does not favor ACI over other less costly
procedures that are potentially as efﬁcacious.
Conclusions and future research
Current clinical research does not support a functional beneﬁt of
ACI techniques over older techniques likemicrofracture2,80,81. There
is, however, a trend towards less complications or need for re-
operation in all arthroscopic and newer-generation ACI tech-
niques22. Histological support for ‘biomechanically superior’ hya-
line cartilage ﬁlling the defect in ACI procedures is lacking, as is
evidence that the presence of this tissue ultimately delays or halts
the development of osteoarthritis79,81. At this time many of the
potential cell sources described above are still experimental, and
may be decades away from clinical practice, if at all.
It is assumed that a multifactorial tissue engineering approach
to cartilage regeneration is ideal e combining cells, and scaffold to
create a biologically active graft. The role of growth factors is still
controversial. There are many questions that still need to be
answered if tissue engineering is to be utilized to repair a chondral
defect with articular cartilage containing biologically active cells.
For example, which cell when differentiated to a chondrocyte
produces a matrix most similar to native hyaline cartilage and will
this tissue decrease the risk of arthritis in those with osteochondral
lesions? How will our evolving understanding of growth factors
and scaffolds impact osteochondral repair? What conditions are
necessary to encourage integration between native cartilage and
the implanted graft? Are biphasic implants the best way to
encourage stable integration of grafts? Do we need to recapitulate
cartilage zonal organization with a deep calciﬁed zone to facilitate
integration and weight bearing?
The literature suggests that single staged procedures, all
arthroscopic techniques, and avoiding periosteal patches appear to
impact complication and revision rates, but there are many other
B. Mollon et al. / Osteoarthritis and Cartilage 21 (2013) 1824e18331830questions that arise when the above is to be applied clinically. Is
there any functional beneﬁt of newer-generation ACI techniques?
How does scaffold-augmented microfracture compare to ACI pro-
cedures? What is the optimal post-operative rehabilitation pro-
cess? Is there a long-term impact on rates of osteoarthritis? Is there
a way to make the process more ﬁnancially feasible?
As stated in this review: our understanding of the factors
inﬂuencing optimization and application of cartilage tissue engi-
neering is expanding. However, the clinical impact of this research
has yet to be truly appreciated as these ﬁndings have yet to be
translated into human use. As new techniques or products are
introduced, decisions on their utility must be predicated on evi-
dence based medicine and functional outcomes. Each new advance
should also be scrutinized for ease of cell harvest and growth,
quality of cartilage produced, and overall cost-effectiveness.
Through all of these ongoing efforts and developments, cartilage
tissue engineering should be a powerful tool for the treatment of
chondral defects.
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